Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' resubmission of the atrial fibrillation medication Multaq is expected to include data from the ongoing ATHENA trial.